companies innovating obesity treatment glp-1 drugs 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth Outlook for obesity in 2025:

The goal is to lose fat, preserve muscle, and improve long-term movement, living, and functioning

Learn what research shows about GLP-1 medications for autoimmune thyroid conditions, safety considerations, and evidence-based treatment options for Hashimoto's thyroiditis.

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.

Overall, the EASD-ADA consensus provides a dynamic framework that supports a multifaceted, patient-centric approach to type 2 diabetes care, aiming to reduce complications, improve quality of life, and promote long-term health outcomes

How is it taken

De Giorgi and colleagues present a comprehensive analysis of pre-clinical and clinical studies examining the role of glucagon-like peptide-1 receptor agonists in mental disorders.